Worldwide breakthrough in Kraków: DK-AT390HCl eliminates colon tumors without damaging normal cells in trials

Researchers from institutions in Kraków, in Polônia, developed a chemical compound calledDK-AT390HClwhich demonstrates high effectiveness in combating rak jelita grubego cells. The announcement took place in December 2025, with tests revealing that the substance selectively attacks cancer cells, preserving healthy ones. Liderado by dr. inż. Damian Kułaga from Politechnika Krakowska, the project involves collaboration with Uniwersytet Rolniczy w Krakowie and Instytut Immunologii i Terapii Doświadczalnej PAN.
O rak jelita grubegorepresents one of the main causes of cancer deaths in the world, with around 2 million new cases diagnosed annually and approximately 900 thousand deaths, according to data from 2022. The new molecule appears as a potential option to improve current treatments, which often cause significant side effects due to lack of selectivity.
In vitro and in vivo tests indicated that theDK-AT390HClsignificantly reduces tumor mass in animal models. The substance already has the protection of four patents granted and two requests in progress, in addition to prospects for European registration.
Mechanism of action of the molecule
O DK-AT390HClit acts precisely by interacting with a specific lipidowa kinaza present in cancer cells. Essa interaction blocks secondary biological processes, including autophagy, which allows tumor cells to survive in adverse conditions, such as during chemotherapy.
The researchers compare the operation to a lock and key system, where the molecule fits perfectly into the target enzyme. Essa precision explains the observed selectivity, with minimal damage to normal cells in direct comparisons.
- Hamowanie autofagii prevents the self-defense of cancer cells.
- Reduction of migration and formation of tumor colonies in laboratory tests.
- Favorable initial safety profile in preliminary in vivo evaluations.
Compound selection process
The team synthesized more than 200 tryptamine-derived substances enriched with triazine and pyrimidine structures. Inicialmente, the compounds were evaluated for activity against triple negative Rak Piersi, but theDK-AT390HClit stood out in subsequent tests for rak jelita grubego.
Interdisciplinary collaborations have enabled detailed analyzes in both cancerous and normal cell lines. The substance showed elevated cytotoksyczność against strains such as SW480 and SW620, common in colorectal cancer studies.
These results motivated additional funding from European funds to advance biological research. The compound reached the TRL4 level of technological maturity, indicating feasibility for pre-clinical stages.
Global rak jelita grubego statistics
Colorectal cancer ranks third in worldwide incidence and second in oncological mortality. Fatores as a late diagnosis contribute to the spread of metastases, complicating treatment in advanced stages.
In Polônia, the disease mainly affects adults, but an increase is observed in age groups under 50 years old. Programas screening, such as colonoscopy, remains essential for early detection.
- Around 2 million new cases per year globally.
- Approximately 900,000 annual related deaths.
- Reduced survival rate in metastatic stages.
Collaborations and funding
The project has support from institutions such as Narodowe Centrum Badań i Rozwoju and Fundacja na rzecz Nauki Polskiej. Parcerias between chemistry, biology and veterinary medicine accelerated development.
Researchers like Dr. Izabela Siemińska, from Uniwersytet Rolniczy, contributed expertise in immunooncology. Essas alliances strengthened experimental validations.
Current focus includes assessment of toxicity and additional molecular mechanisms. Discussões on commercialization involves the Politechnika Krakowska technology transfer center.
Intellectual protection achieved
Four patents already protect aspects of the synthesis and application ofDK-AT390HCl. Duas additional requests are under review, including the international PCT procedure.
This coverage reinforces the innovative potential of the molecule as a first-in-class candidate. The registrations cover specific compositions and therapeutic uses against colorectal tumors.
The perspective of European protection expands the possibilities of partnerships with the pharmaceutical industry. Tais alliances would be necessary to fund future clinical phases.
Preliminary in vivo tests
Evaluations in animal models confirmed a substantial reduction in tumor mass. The compound demonstrated a favorable maximum tolerated dose in initial studies.
Molecular research in tumor tissues has validated the blockade of pathways associated with cancer progression. Esses data supports continuation to preclinical refinements.
Results indicate that guzos responded with almost complete regression in certain protocols. Continuous Monitoramento checks consistency of these effects.
Next steps in development
The team is looking for pharmaceutical partners to advance to the clinical phases, which require high investments. Additional Estudos focus on confirming selectivity in human tissues.
The compound represents an advance in targeted therapies for resistant cancers. Pesquisas parallels explore combinations with existing treatments.
Monitoring of common mutations, such as KRAS and BRAF, integrates future analyses. Esses efforts aim to maximize clinical applicability.






